Loading...
•
Jun 30, 2024
United Therapeutics Q2 2024 Earnings Report
Reported a record revenue driven by continued traction for Tyvaso and strong fundamentals for other products.
Key Takeaways
United Therapeutics reported a 20% year-over-year increase in total revenues, reaching $714.9 million in the second quarter of 2024, compared to $596.5 million in the second quarter of 2023. The growth was primarily driven by Tyvaso, Remodulin, Orenitram and Unituxin.
Total revenues grew by 20% year-over-year to $714.9 million.
Net income increased by 7% to $278.1 million.
Tyvaso revenues increased by 25% to $398.2 million.
The company expects data from its innovative clinical pipeline next year.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
The company anticipates near-term commercial growth and the progress of its organ manufacturing programs.
Positive Outlook
- Anticipated near-term commercial growth.
- Expected progress of organ manufacturing programs.
- Innovative clinical pipeline potential.
- Focus on unmet medical needs of patients.
- Development of novel pharmaceutical therapies.
Challenges Ahead
- Risks and uncertainties described in periodic reports.
- Potential differences between actual and anticipated results.
- Cautionary statements in periodic reports.
- Risk factors in SEC filings.
- No obligation to update or revise information.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...